Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors.
autoimmune diseases
immunotherapy
patient education
qualitative interviews
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Aug 2023
07 Aug 2023
Historique:
received:
11
07
2023
revised:
25
07
2023
accepted:
31
07
2023
medline:
12
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Patients with pre-existing autoimmune disorders and cancer considering immune checkpoint inhibitors (ICIs) need to receive balanced information about the benefits and risk of developing immune-related adverse events (irAEs) and flare-ups of their autoimmune disease. To assess the learning needs of patients with cancer and pre-existing autoimmune disease regarding ICI treatment, we interviewed 29 patients with autoimmune disease and cancer from a comprehensive cancer center, of whom 20 had received ICI and 9 were candidates to receive ICI at a US Cancer Center. In-depth semi-structured interviews were conducted from August 2021 and January 2022. Interviewee's opinions and preferences about content and information delivery methods were collected. We recorded and transcribed interviews and analyzed them using thematic analysis. Half of the participants were female, and their median (SD) age was 62.9 (±10.9) years. The identified health information needs included the following: (1) information on irAEs and autoimmune disease flare-ups; (2) benefits of ICI; (3) ICI mechanism in the context of autoimmune disease; (4) management of flare-ups; (5) reasons for stopping or modifying cancer or autoimmune disease treatment; (6) likelihood of autoimmune disease progression or organ damage; and (7) lifestyle changes that could help avoid irAEs. Patients who had received ICI and those who had not yet received treatment reported similar needs, although patients who had received ICI had more questions about cancer treatment modifications. Patients also expressed the need to better understand when to contact their provider and how to share information with multiple providers. Most patients wanted to receive information in visual formats for review at home and at their own pace. Patients expressed interest in having educational tools to facilitate shared decision-making with their physicians, and they identified several areas of health information concerning therapy with ICI. They also highlighted the importance of communication among their various providers.
Identifiants
pubmed: 37568819
pii: cancers15154004
doi: 10.3390/cancers15154004
pmc: PMC10416973
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : CA237619
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA237619
Pays : United States
Organisme : NIAMS NIH HHS
ID : K08 AR079587
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Références
JAMA Oncol. 2016 Nov 1;2(11):1507-1508
pubmed: 27262099
Patient. 2020 Aug;13(4):457-467
pubmed: 32472503
BMC Rheumatol. 2020 Aug 01;4:32
pubmed: 32766511
Support Care Cancer. 2017 Jul;25(7):2155-2167
pubmed: 28247127
Cancers (Basel). 2023 May 10;15(10):
pubmed: 37345026
J Cancer Res Clin Oncol. 2023 Aug;149(9):6341-6350
pubmed: 36752908
Arthritis Rheumatol. 2019 Dec;71(12):2100-2111
pubmed: 31379105
Melanoma Res. 2019 Dec;29(6):626-634
pubmed: 30688762
PLoS One. 2022 Oct 10;17(10):e0275676
pubmed: 36215234
BMC Cancer. 2020 Aug 10;20(1):743
pubmed: 32778064
Ann Oncol. 2020 Jun;31(6):724-744
pubmed: 32194150
Oncol Nurs Forum. 2014 Sep;41(5):545-7
pubmed: 25158659
J Cancer Res Clin Oncol. 2020 Dec;146(12):3189-3198
pubmed: 32813113
J Cancer Surviv. 2020 Jun;14(3):363-376
pubmed: 31950409
Br J Dermatol. 2022 Sep;187(3):381-391
pubmed: 35596713
Aliment Pharmacol Ther. 2021 Feb;53(3):374-382
pubmed: 33314269
Support Care Cancer. 2019 May;27(5):1845-1852
pubmed: 30178142
Cancers (Basel). 2023 Aug 07;15(15):
pubmed: 37568819
Clin J Oncol Nurs. 2019 Jun 1;23(3):271-280
pubmed: 31099804
Adm Policy Ment Health. 2015 Sep;42(5):533-44
pubmed: 24193818
Thorac Cancer. 2020 Jan;11(1):198-202
pubmed: 31762209
Clin Genitourin Cancer. 2022 Apr;20(2):114-122
pubmed: 34903481
Oncologist. 2019 Nov;24(11):e1190-e1196
pubmed: 31015314
Support Care Cancer. 2022 Sep;30(9):7249-7260
pubmed: 35589878
Acad Med. 2014 Sep;89(9):1245-51
pubmed: 24979285
Eur J Gen Pract. 2018 Dec;24(1):120-124
pubmed: 29202616
J Glob Oncol. 2019 Jul;5:1-6
pubmed: 31283411
Cancer Med. 2020 May;9(9):3015-3022
pubmed: 32119767
Front Oncol. 2021 Feb 22;11:625872
pubmed: 33692958